Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is believed to be an effective treatment for high-risk (HR) T-cell lymphoblastic leukaemia/lymphoma (T-ALL/LBL), a rare but highly aggres
The primary objective of this study is to compare the three study arms of lower, medium, and higher dose platelet therapy with respect to the percentage of patients experiencing at least one episode o
Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) is difficult in older patients with comorbidities and high-risk disease factors. Venetoclax, the first-in-class
